Objectives: To measure plasma pro-apoptotic and pro-necrotic activity in severe acute kidney injury (AKI) patients within a randomized controlled trial of continuous veno-venous hemofiltration with high cut-off filters (CVVH-HCO) versus standard filters (CVVH-Std). Methods: We measured pro-apoptotic and pro-necrotic plasma activity by trypan blue exclusion cell viability assay, detection of DNA fragmentation, and by determination of caspase-3 activity and annexin V-based apoptosis and necrosis detection assay. Results: Compared to no apoptosis or necrosis after incubation with healthy plasma, 14-18% of cells showed apoptosis and 4-8% showed necrosis after incubation with plasma from AKI patients. When comparing different measures of pro-apoptotic or pro-necrotic activity, CVVH-HCO and CVVH-Std showed no differential effects on such activity, which remained high over the first 3 days of treatment. However, using annexin V-FITC, there was a significant drop in pro-apoptotic activity across the filter for the CVVH-HCO group (p = 0.043) but not for the CVVH-Std group (p = 0.327) and a significant difference between the two groups (CVVH-HCO vs. CVVH-Std p = 0.006). Conclusions: Patients with severe AKI have increased pro-apoptotic and pro-necrotic activity. Although on single-pass effect assessment, CVVH-HCO was superior to CVVH-Std in decreasing annexin V-FITC-assessed pro-apoptotic activity, there was no overall attenuation of such activity during the first 3 days of treatment.

Keywords:
Sepsis, Acute kidney injury, Hemofiltration, High cut-off filters, Apoptosis
1.
Lydon A, Martyn JA: Apoptosis in critical illness. Int Anesthesiol Clin 2003;41:65-77.
2.
Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R: Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008;36(suppl 4):S198-S203.
3.
Rosen S, Heyman SN: Difficulties in understanding human ‘acute tubular necrosis': limited data and flawed animal models. Kidney Int 2001;60:1220-1224.
4.
Kaushal GP, Basnakian AG, Shah SV: Apoptotic pathways in ischemic acute renal failure. Kidney Int 2004;66:500-506.
5.
Linkermann A, De Zen F, Weinberg J, Kunzendorf U, Krautwald S: Programmed necrosis in acute kidney injury. Nephrol Dial Transplant 2012;27:3412-3419.
6.
Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-1251.
7.
Jacobs R, Honore PM, Joannes-Boyau O, Boer W, De Regt J, De Waele E, et al: Septic acute kidney injury: the culprit is inflammatory apoptosis rather than ischemic necrosis. Blood Purif 2011;32:262-265.
8.
Bordoni V, Bolgan I, Brendolan A, Crepaldi C, Gastaldon F, D'intini V, et al: Caspase-3 and -8 activation and cytokine removal with a novel cellulose triacetate super-permeable membrane in an in vitro sepsis model. Int J Artif Organs 2003;26:897-905.
9.
Cantaluppi V, Assenzio B, Pasero D, Romanazzi GM, Pacitti A, Lanfranco G, et al: Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 2008;34:1638-1645.
10.
Boschetti-de-Fierro A, Voigt M, Storr M, Krause B: Extended characterization of a new class of membranes for blood purification: the high cut-off membranes. Int J Artif Organs 2013;36:455-463.
11.
Morgera S, Rocktäschel J, Haase M, Lehmann C, von Heymann C, Ziemer S, Priem F, Hocher B, Göhl H, Kox WJ, Buder HW, Neumayer HH: Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003;29:1989-1995.
12.
Atan R, Crosbie D, Bellomo R: Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif 2012;33:88-100.
13.
Atan R, Crosbie D, Bellomo R: Techniques of extracorporeal cytokine removal: a systematic review of the literature on animal experimental studies. Int J Artif Organs 2013;36:149-158.
14.
Atan R, Crosbie DC, Bellomo R: Techniques of extracorporeal cytokine removal: a systematic review of human studies. Ren Fail 2013;35:1061-1070.
15.
Sundström C, Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int J Cancer 1976;17:565-577.
16.
Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995;182:1545-1556.
17.
Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-2216.
18.
Diaz C, Schroit AJ: Role of translocases in the generation of phosphatidylserine asymmetry. J Membr Biol 1996;151:1-9.
19.
Homburg CH, de Haas M, von dem Borne AE, Verhoeven AJ, Reutelingsperger CP, Roos D: Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood 1995;85:532-540.
20.
Verhoven B, Schlegel RA, Williamson P: Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995;182:1597-1601.
21.
Bilbault P, Lavaux T, Lahlou A, Uring-Lambert B, Gaub MP, Ratomponirina C, et al: Transient Bcl-2 gene down-expression in circulating mononuclear cells of severe sepsis patients who died despite appropriate intensive care. Intensive Care Med 2004;30:408-415.
22.
Giamarellos-Bourboulis EJ, Routsi C, Plachouras D, Markaki V, Raftogiannis M, Zervakis D, et al: Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock? Crit Care 2006;10:R76.
23.
Weiss M, Elsharkawi M, Welt K, Schneider EM: Transient leukocytosis, granulocyte colony-stimulating factor plasma concentrations, and apoptosis determined by binding of Annexin V by peripheral leukocytes in patients with severe sepsis. Ann NY Acad Sci 2003;1010:742-747.
24.
Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, Remuzzi G: Efficacy of coupled plasma filtration adsorption in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open 2014;4:e003536.
25.
Rachoin JS, Foster D, Dellinger RP: Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES. Contrib Nephrol. Basel, Karger, 2010, vol 167, pp 111-118.
26.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-2452.
27.
Havasi A, Borkan SC: Apoptosis and acute kidney injury. Kidney Int 2011;80:29-40.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.